Schmidlen Tara, Schwartz Marci, DiLoreto Kristy, Kirchner H Lester, Sturm Amy C
Geisinger, Genomic Medicine Institute, Danville, PA, USA.
The Pennsylvania State University, College of Health and Human Development, University Park, PA, USA.
J Genet Couns. 2019 Dec;28(6):1166-1177. doi: 10.1002/jgc4.1169. Epub 2019 Sep 24.
A barrier to incorporating genomics more broadly is limited access to providers with genomics expertise. Chatbots are a technology-based simulated conversation used in scaling communications. Geisinger and Clear Genetics, Inc. have developed chatbots to facilitate communication with participants receiving clinically actionable genetic variants from the MyCode Community Health Initiative (MyCode ). The consent chatbot walks patients through the consent allowing them to opt to receive more or less detail on key topics (goals, benefits, risks, etc.). The follow-up chatbot reminds participants of suggested actions following result receipt and the cascade chatbot can be sent to at-risk relatives by participants to share their genetic test results and facilitate cascade testing. To explore the acceptability, usability, and understanding of the study consent, post-result follow-up and cascade testing chatbots, we conducted six focus groups with MyCode participants. Sixty-two individuals participated in a focus group (n = 33 consent chatbot, n = 29 follow-up and cascade chatbot). Participants were mostly female (n = 42, 68%), Caucasian (n = 58, 94%), college-educated (n = 33,53%), retirees (n = 38, 61%), and of age 56 years or older (n = 52, 84%). Few participants reported that they knew what a chatbot was (n = 10, 16%), and a small number reported that they had used a chatbot (n = 5, 8%). Qualitative analysis of transcripts and notes from focus groups revealed four main themes: (a) overall impressions, (b) suggested improvements, (c) concerns and limitations, and (d) implementation. Participants supported using chatbots to consent for genomics research and to interact with healthcare providers for care coordination following receipt of genomic results. Most expressed willingness to use a chatbot to share genetic information with relatives. The consent chatbot presents an engaging alternative to deliver content challenging to comprehend in traditional paper or in-person consent. The cascade and follow-up chatbots may be acceptable, user-friendly, scalable approaches to manage ancillary genetic counseling tasks.
更广泛地纳入基因组学的一个障碍是,获得具备基因组学专业知识的医疗服务提供者的机会有限。聊天机器人是一种基于技术的模拟对话,用于扩大沟通范围。盖辛格医疗集团(Geisinger)和Clear Genetics公司开发了聊天机器人,以促进与参与“我的代码”社区健康倡议(MyCode)并收到具有临床可操作性基因变异结果的参与者进行沟通。同意聊天机器人引导患者完成同意流程,使他们能够选择接收更多或更少关于关键主题(目标、益处、风险等)的详细信息。随访聊天机器人在参与者收到结果后提醒他们建议采取的行动,而级联聊天机器人可由参与者发送给有风险的亲属,以分享他们的基因检测结果并促进级联检测。为了探究研究同意、结果后随访以及级联检测聊天机器人的可接受性、可用性和理解情况,我们与MyCode参与者进行了六个焦点小组讨论。62人参加了焦点小组(同意聊天机器人组33人,随访和级联聊天机器人组29人)。参与者大多为女性(42人,68%)、白种人(58人,94%)、受过大学教育(33人,53%)、退休人员(38人,61%),年龄在56岁及以上(52人,84%)。很少有参与者表示知道什么是聊天机器人(10人,16%),少数人表示使用过聊天机器人(5人,8%)。对焦点小组的文字记录和笔记进行定性分析,揭示了四个主要主题:(a)总体印象,(b)改进建议,(c)担忧与局限,(d)实施情况。参与者支持使用聊天机器人来同意进行基因组学研究,并在收到基因组结果后与医疗服务提供者互动以进行护理协调。大多数人表示愿意使用聊天机器人与亲属分享基因信息。同意聊天机器人为传递传统纸质或面对面同意书中难以理解的内容提供了一种引人入胜的替代方式。级联和随访聊天机器人可能是管理辅助基因咨询任务的可接受、用户友好且可扩展的方法。